AIM — AIM ImmunoTech Share News
0.000.00%
Last trade - 00:00- $8.65m
- $6.99m
- $0.09m
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Brief: Aim Immunotech Provides Routine Update On Annual Filings
U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin
ImmunoTech jumps after Japan grants patent for experimental cancer drug
Brief: Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors
Brief: Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million
Brief: AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer
Brief: Aim Immunotech Announces Extension Of Subscription Period
Brief: Aim Immunotech Announces Commencement Of Rights Offering
Brief: Aim Immunotech Reports Year-End Positive Phase 2 Interim Progress For Ampligen® (Rintatolimod) Plus Astrazeneca’S Imfinzi® (Durvalumab) In Pancreatic Cancer
Brief: Aim Immunotech enters Note Purchase Agreement with Streeterville Capital, says SEC Filing
Brief: Aim Immunotech Reports Third Quarter 2025 Financial Results And Highlights Continued Progress Across Pipeline With Strategic Focus On Pancreatic Cancer Clinical Program
Brief: Aim Immunotech Inc - Ampligen With Imfinzi Shows Positive Results In Pancreatic Cancer
Brief: Aim Immunotech Announces Closing Of $8.0 Million Public Offering
Brief: AIM ImmunoTech Reports Positive Mid-Year Safety And Efficacy Data From Phase 2 Study Evaluating Ampligen® (Rintatolimod) In Combination With AstraZeneca’S Imfinzi® (Durvalumab) For The Treatment Of Pancreatic Cancer
Brief: Aim Immunotech Announces 1-For-100 Reverse Stock Split